Developer docs
API playgroundTry for free, no card

Search company profiles

Firalis

Full company profile

uuid00099yr

Namestring
Firalis
Legal namestring
Firalis S.A.
Websiteurl
firalis.com
Company typeenum
Private
Founded yearint
2008
Descriptiontext

Firalis S.A. is a private biotechnology company founded in 2008 in Huningue, France, at the triple border of France-Germany-Switzerland within the BioValley cluster adjacent to Basel. The company specializes in biomarker discovery, development, and regulatory qualification for precision medicine, operating a multi-omics platform that combines proteomics (Olink Proseek panels, Quanterix Simoa), genomics (Illumina NextSeq 500 NGS), and transcriptomics. Its proprietary product portfolio includes the FIMICS cardiac long non-coding RNA (lncRNA) panel quantifying 3,233 cardiac-enriched targets, the BIOPRED mRNA panel for inflammatory-autoimmune disorders, NEUROLINCS for neurodegenerative disease, and the MEMORYLINC blood-based Alzheimer's test; the affiliate Amoneta Diagnostics received CE-IVDR marking for the APO-Easy Genotyping Kit in 2024.

Firalis operates a hybrid business model spanning contract research organization (CRO) services, Research-Use-Only (RUO) and In-Vitro Diagnostic (IVD) kit commercialization, EU-funded research grants, and third-party CE-IVDR certification services delivered through a new bioproduction facility. The company sells directly to pharmaceutical and biotechnology clients, including named partners such as Sanofi and Servier in the PACIFIC heart failure consortium, Astellas, QuantaMatrix, and Seoul National University Hospital, with distribution partnerships in South Korea and Japan. Pricing is quotation-based, and the company maintains certifications across ISO 13485, ISO 17025, ISO 9001, ISO 14001, and NF S 96-900.

Revenue mechanics rely on a combination of professional services fees, one-time kit sales, non-dilutive grant funding (cumulative >€20M from Horizon 2020, IMI, FP7, Eurostars, Bpifrance, and ANR), and approximately €3M in venture capital and crowdfunding. The company employs 60 people (25% PhDs) and is investing in a 4,000 sqm bioproduction facility in Huningue (€7.2M total project; €1.284M from France 2030) expected operational by 2026, with planned headcount growth of more than 100 jobs by 2029.

Short descriptiontext

Firalis is a France-based biotechnology company offering proprietary multi-omics biomarker panels (cardiac, neurodegenerative, autoimmune) and CRO services in proteomics, genomics, and transcriptomics to pharmaceutical, biotechnology, and academic clients.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersHuningue, France
HQ citystring
Huningue
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biomarker discovery services, in vitro diagnostics kits, multi-omics analysis, clinical research services, precision medicine diagnostics
Industry3 codes
PRIMARYHLAAAMAJ
Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAAMAL
Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGADAG
Proteomics & Biomarker Analytical Testing
NAICS code3 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Medical and Diagnostic Laboratories6215
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Commercial Physical & Biological Research8731
Product category
Biomarker Diagnostics & Contract Research Services
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1CRO Biomarker Services
TypeProfessional Services
Description

Provides comprehensive biomarker services from discovery to clinical qualification including proteomics, genomics, transcriptomics, assay development, and biobanking services to pharmaceutical and biotech companies.

firalis.com
2RUO and IVD Kit Sales
TypeOne Time License
Description

Commercialization of Research-Use-Only and In-Vitro Diagnostic kits including FIMICS, BIOPRED, NEUROLINCS, MEMORYLINC panels, and ELISA kits for cardiovascular, neurodegenerative, and inflammatory diseases.

firalis.com
3Research Grants
TypeLicensing Royalties
Description

European Commission and government funding from programs including IMI, FP7, Eurostars, Horizon 2020, France 2030 for R&D projects.

firalis.com
4CE-IVDR Certification Services
TypeProfessional Services
Description

Third-party diagnostic candidates offered CE-IVDR certification services at new bioproduction facility.

firalis.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Pricing details1 tier
1Custom quotation-based pricing
ModelOtherBilling cadenceMulti-year contract
Notes

Contact-based pricing model via quotation request form for clinical research services

firalis.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 6 records shown
1Firalis Molecular Precision
Description

Subsidiary brand for large-scale protein identification and genomics services including Olink, Quanterix, and Next Generation Sequencing

firalis.com
+5 more records
Core offering1 text field

Firalis provides biomarker discovery, development, and regulatory qualification services to pharmaceutical, biotech, and academic clients through its multi-omics CRO platform (proteomics, genomics, transcriptomics, assay development, biobanking). The company also manufactures and commercializes proprietary RUO and IVD biomarker kits — FIMICS (cardiac lncRNAs), BIOPRED (inflammatory mRNAs), NEUROLINCS and MEMORYLINC (neurodegenerative lncRNAs), ELISA kits, and IVD products such as EasyCOV (COVID-19 saliva test) and APO-Easy (Alzheimer's APOE genotyping). All production takes place in ISO 13485/ISO 17025/NF S 96-900 certified facilities in Huningue, France.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 100+ clinical and pre-clinical biomarker research projects completed
+5 more records
Product overview1 text field

Firalis is a biotechnology company offering a comprehensive biomarker-based diagnostic portfolio combined with CRO services. The product suite includes RUO (Research-Use-Only) diagnostic kits (FIMICS for cardiac lncRNAs, MEMORYLINC and NEUROLINCS for neurodegenerative diseases, BIOPRED for inflammatory disorders, ELISA Kits) and IVD products (EasyCOV COVID-19 test, APO-Easy Genotyping Kit). The company provides biomarker services including proteomics (Olink, Quanterix platforms), genomics (NGS, Illumina NextSeq 500), and assay development. All products and services are supported by GMP-compliant facilities certified ISO 13485, ISO 17025, ISO 9001, and biobanking under NF S 96-900 standards.

Product and service13 records
1FIMICS
CategoryRUO Diagnostic Kit
Description

Long non-coding RNA (lncRNA) research-use-only panel quantifying 3,233 cardiac-enriched lncRNAs in peripheral blood samples for characterization of patients with diverse cardiac disorders and toxicities, leveraging NGS with ~55,000 capture probes.

2MEMORYLINC
CategoryRUO Diagnostic Kit
Description

Blood-based non-coding RNA RUO panel for early diagnosis of Alzheimer's disease and other neurodegenerative conditions.

3NEUROLINCS
CategoryRUO Diagnostic Kit
Description

Targeted sequencing RUO panel quantifying ~7,500 brain-enriched lncRNAs from blood samples for research on cognitive impairment, Alzheimer's, and neurodegenerative diseases.

4BIOPRED
CategoryRUO Diagnostic Kit
Description

mRNA targeted gene sequencing RUO panel quantifying over 2,100 mRNAs in whole blood (PAXgene RNA tubes) for inflammatory-autoimmune disorder research, using extraction-free HTG EdgeSeq chemistry with reproducibility mean R > 0.99.

5ELISA Kits
CategoryRUO/IVD Diagnostic Kit
Description

Colorimetric sandwich ELISA kits developed and validated by Firalis for quantitative biomarker measurement in blood-derived matrix samples.

6EasyCOV COVID-19 Saliva Test
CategoryIVD Diagnostic Kit
Description

CE-marked, non-invasive saliva-based IVD test using colorimetric detection for SARS-CoV-2, with HAS validation and reimbursement recommendation in France.

7APO-Easy Genotyping Kit
CategoryIVD Diagnostic Kit
Description

CE-IVDR certified qualitative IVD real-time PCR test for detection of APOE genotypes (rs429358 and rs7412) supporting Alzheimer's disease diagnostics and risk stratification.

8Proteomics CRO Services (Olink / Quanterix Simoa)
CategoryCRO Research Services
Description

CRO biomarker services using Olink Explore, Target, and Flex Proximity Extension Assay platforms (92+ biomarkers per panel from <50 µl samples) plus Quanterix Simoa ultra-low protein quantification.

9Genomics CRO Services (Illumina NextSeq 500 NGS)
CategoryCRO Research Services
Description

CRO genomics services delivering Illumina Propel-certified NextSeq 500 NGS including RNA-Seq, miRNA profiling, exome sequencing, methylation analysis, single-cell sequencing, spatial transcriptomics, and custom RT-qPCR.

10Assay Development & Production Services
CategoryCRO Research Services
Description

CRO assay development, validation, and ISO 13485/ISO 17025-compliant production of biological materials and CE-marked IVD kits for pharma and diagnostic partners.

11Clinical Samples / Biobank Services
CategoryBiobanking Services
Description

Clinical biological samples and biobanking services operated under NF S 96-900 certification, with Firalis' biobank moving toward registration as a BBMRI-ERIC node.

12Recombinant Proteins / Calibrants
CategoryResearch Reagents
Description

Catalog of recombinant proteins and calibrants for research and diagnostic assay development.

13Monoclonal Antibodies
CategoryResearch Reagents
Description

Catalog monoclonal antibodies for biomarker detection and diagnostic assay development.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership23 partners
1ONCOSCREEN Consortium (~40 partners)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-05-12
Description

EU Horizon Europe project for colorectal cancer screening. €14 million project integrating AI, genomic biomarkers, and citizen feedback for early CRC detection.

firalis.com
2VOLABIOS Consortium (18 partners)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Horizon Europe project for schizophrenia diagnosis using multi-omics volatolomics biomarkers. Firalis leads VOC biomarker validation with genomics, proteomics, transcriptomics expertise.

firalis.com
3Rostock Medicine University
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-06-24
Description

CombiDiag doctoral network coordinator hosting summer school at Firalis for Alzheimer's biomarker research training.

firalis.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-04-03
Description

PARADISE project coordinator for personalized prediction tool for autoimmune disease recurrence. Project kick-off April 2023 for three-year duration.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-11-01
Description

COVIRNA project coordinator for COVID-19 cardiovascular complications diagnostic test development. FIMICS panel based prognostic device development with 3.88 M€ EC funding.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2020-08-06
Description

Olink certified service provider offering Proseek panels for COVID-19 research at exceptional prices. Each panel measures 92 biomarkers simultaneously.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-06-18
Description

EasyCOV saliva test production partnership for COVID-19 diagnostic. Firalis produces tests at industrial scale. HAS validated for use and reimbursement.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-06-18
Description

EasyCOV consortium partner for COVID-19 saliva test development with validation by French health authorities.

9VOGO
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-06-18
Description

EasyCOV consortium partner providing technology startup expertise for COVID-19 diagnostic test development.

firalis.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2019-05-28
Description

Japanese pharmaceutical company collaboration beginning for biomarker research services.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-01-21
Description

PACIFIC consortium partner (5-year project) for redefining heart failure with preserved ejection fraction (HFpEF). Sanofi leads consortium with Firalis providing biomarker expertise.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-01-21
Description

PACIFIC consortium partner contributing expertise in data management and biostatistics for heart failure research alongside Sanofi.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-01-21
Description

PACIFIC consortium coordinator for clinical study with five cardiology hospitals and clinical investigation centers recruiting patients.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-01-21
Description

PACIFIC consortium partner providing expertise in biomedical ultrasound and cardiovascular imaging analysis through research units.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2019-01-21
Description

PACIFIC consortium partner developing connected textiles for remote patient monitoring in heart failure management.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2019-01-21
Description

PACIFIC consortium partner developing AI image analysis software for cardiac imaging.

17Fealinx
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2019-01-21
Description

PACIFIC consortium partner developing AI algorithms for heart failure data analysis.

firalis.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-09-19
Description

Co-development and commercialization agreement for FIMICS lncRNA panel using Celemics targeted enrichment technology for Next-Generation Sequencing. Joint product development.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2018-05-23
Description

Platform partner for Biopred panel development using HTG EdgeSeq system for extraction-free targeted mRNA profiling.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2018-05-20
Description

Propel certified partner for NextSeq 500 sequencing platform ensuring high quality sequencing data and best practice compliance.

21CHU de Toulouse
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2017-06-17
Description

HeartLinc project European clinical partner for AMI patient profiling (150 patients in France).

firalis.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2017-03-24
Description

Co-development and distribution agreement for IVD products in South Korea. Partner in HeartLinc project developing heart failure diagnostic test on Fi-MAP platform.

23Seoul National University Hospital (SNUH)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2017-03-24
Description

HeartLinc project partner for heart failure diagnostic test validation in Asian AMI patients (150 patients).

firalis.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Qiagen is a global molecular sample-prep and diagnostic company offering companion diagnostics, IVD kits, and biomarker services. Broader portfolio but directly competes with Firalis on IVD assay development and pharmaceutical biomarker services for pharma partners.

TypeDirect peer
Description

NanoString offers spatial transcriptomics and targeted gene expression profiling (GeoMx, nCounter) serving the same pharma and translational research customer base as Firalis's genomics services, including direct overlap with Firalis's spatial transcriptomics service line.

TypeBroad incumbent
Description

Myriad is an established molecular diagnostics company commercializing blood-based and tissue-based companion and IVD tests (e.g., myChoice HRD, Vectra). Firalis's IVD strategy for cardiovascular and neurodegenerative biomarkers follows a similar companion-diagnostic commercialization model at smaller scale.

TypeDirect peer
Description

Quanterix provides the Simoa ultra-sensitive protein detection platform used by Firalis as a certified service provider. Comparable biomarker detection technology for neurology and inflammation indications and overlapping pharma/biotech customer base in blood-based biomarker discovery.

TypeEmerging player
Description

Biodesix is a blood-based diagnostics company developing proteomic and multi-omic tests for oncology and lung disease. Comparable as an emerging blood-based biomarker diagnostic company pursuing similar indications and reimbursement pathways as Firalis's MEMORYLINC and FIMICS.

TypeDirect peer
Description

Eurofins Genomics is a global genomic services and biomarker CRO offering NGS, qPCR, genotyping, and biomarker assay services to pharma and academic customers. Directly comparable to Firalis's genomics/transcriptomics CRO offering and competing for the same European pharma R&D budget.

TypeDirect peer
Description

HTG Molecular Diagnostics develops the EdgeSeq extraction-free targeted mRNA profiling platform that Firalis uses for the BIOPRED panel. Both serve pharma biomarker discovery with targeted RNA panels, making HTG a partner-and-competitor with direct product overlap in inflammatory-autoimmune profiling.

TypeBroad incumbent
Description

Bio-Rad provides life science research and clinical diagnostics products including ddPCR, digital ELISA, and biomarker kits. Overlaps with Firalis's ELISA kit offerings and proteomics CRO services for pharma and academic customers.

TypeEmerging player
Description

QuantaMatrix developed the Fi-MAP multiplexed gene-expression IVD platform used in the HeartLinc project with Firalis and Seoul National University Hospital. Overlapping focus on molecular diagnostics for infectious disease and cardiology with similar Asian market channel strategy.

TypeEmerging player
Description

Celemics is a Seoul-based targeted NGS enrichment and sequencing company that co-developed the FIMICS panel with Firalis. Comparable as a smaller emerging player in the targeted sequencing/biomarker panel market and a partner-competitor for next-gen sequencing diagnostics.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration7 records

Each record includes

Title, Type, Description, Source

AI capability8 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance8 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Firalis

Biomarker Diagnostics & Contract Research Servicesfiralis.com

Firalis is a France-based biotechnology company offering proprietary multi-omics biomarker panels (cardiac, neurodegenerative, autoimmune) and CRO services in proteomics, genomics, and transcriptomics to pharmaceutical, biotechnology, and academic clients.

What Firalis does

Firalis S.A. is a private biotechnology company founded in 2008 in Huningue, France, at the triple border of France-Germany-Switzerland within the BioValley cluster adjacent to Basel. The company specializes in biomarker discovery, development, and regulatory qualification for precision medicine, operating a multi-omics platform that combines proteomics (Olink Proseek panels, Quanterix Simoa), genomics (Illumina NextSeq 500 NGS), and transcriptomics. Its proprietary product portfolio includes the FIMICS cardiac long non-coding RNA (lncRNA) panel quantifying 3,233 cardiac-enriched targets, the BIOPRED mRNA panel for inflammatory-autoimmune disorders, NEUROLINCS for neurodegenerative disease, and the MEMORYLINC blood-based Alzheimer's test; the affiliate Amoneta Diagnostics received CE-IVDR marking for the APO-Easy Genotyping Kit in 2024.

Firalis operates a hybrid business model spanning contract research organization (CRO) services, Research-Use-Only (RUO) and In-Vitro Diagnostic (IVD) kit commercialization, EU-funded research grants, and third-party CE-IVDR certification services delivered through a new bioproduction facility. The company sells directly to pharmaceutical and biotechnology clients, including named partners such as Sanofi and Servier in the PACIFIC heart failure consortium, Astellas, QuantaMatrix, and Seoul National University Hospital, with distribution partnerships in South Korea and Japan. Pricing is quotation-based, and the company maintains certifications across ISO 13485, ISO 17025, ISO 9001, ISO 14001, and NF S 96-900.

Revenue mechanics rely on a combination of professional services fees, one-time kit sales, non-dilutive grant funding (cumulative >€20M from Horizon 2020, IMI, FP7, Eurostars, Bpifrance, and ANR), and approximately €3M in venture capital and crowdfunding. The company employs 60 people (25% PhDs) and is investing in a 4,000 sqm bioproduction facility in Huningue (€7.2M total project; €1.284M from France 2030) expected operational by 2026, with planned headcount growth of more than 100 jobs by 2029.

Firalis firmographics

Firmographics
Name
Firalis
Legal name
Firalis S.A.
Website
https://firalis.com
Company type
Private
Founded year
2008
Operating status
Operating
Headcount range
11–50 employees
Short description
Firalis is a France-based biotechnology company offering proprietary multi-omics biomarker panels (cardiac, neurodegenerative, autoimmune) and CRO services in proteomics, genomics, and transcriptomics to pharmaceutical, biotechnology, and academic clients.
Ownership category
akta.pro rank

Firalis industry classification

Industry
Product category
Biomarker Diagnostics & Contract Research Services
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical and Diagnostic Laboratories (6215)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAMAJ
Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAAMAL
Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGADAG
Proteomics & Biomarker Analytical Testing

Keywords

  • Biomarker discovery services
  • In vitro diagnostics kits
  • Multi-omics analysis
  • Clinical research services
  • Precision medicine diagnostics

Where Firalis is headquartered

Location

Headquarters

HQ city
Huningue
HQ country
France
HQ region
Europe

Offices4 records

Markets served

Firalis business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. CRO Biomarker Services: Provides comprehensive biomarker services from discovery to clinical qualification including proteomics, genomics, transcriptomics, assay development, and biobanking services to pharmaceutical and biotech companies.
  2. RUO and IVD Kit Sales: Commercialization of Research-Use-Only and In-Vitro Diagnostic kits including FIMICS, BIOPRED, NEUROLINCS, MEMORYLINC panels, and ELISA kits for cardiovascular, neurodegenerative, and inflammatory diseases.
  3. Research Grants: European Commission and government funding from programs including IMI, FP7, Eurostars, Horizon 2020, France 2030 for R&D projects.
  4. CE-IVDR Certification Services: Third-party diagnostic candidates offered CE-IVDR certification services at new bioproduction facility.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom quotation-based pricing

Go-to-market motion3 records

Distribution channels3 records

Marketing channels7 records

Firalis product offering

Product offering

Core offering

Firalis provides biomarker discovery, development, and regulatory qualification services to pharmaceutical, biotech, and academic clients through its multi-omics CRO platform (proteomics, genomics, transcriptomics, assay development, biobanking). The company also manufactures and commercializes proprietary RUO and IVD biomarker kits — FIMICS (cardiac lncRNAs), BIOPRED (inflammatory mRNAs), NEUROLINCS and MEMORYLINC (neurodegenerative lncRNAs), ELISA kits, and IVD products such as EasyCOV (COVID-19 saliva test) and APO-Easy (Alzheimer's APOE genotyping). All production takes place in ISO 13485/ISO 17025/NF S 96-900 certified facilities in Huningue, France.

Product overview

Firalis is a biotechnology company offering a comprehensive biomarker-based diagnostic portfolio combined with CRO services. The product suite includes RUO (Research-Use-Only) diagnostic kits (FIMICS for cardiac lncRNAs, MEMORYLINC and NEUROLINCS for neurodegenerative diseases, BIOPRED for inflammatory disorders, ELISA Kits) and IVD products (EasyCOV COVID-19 test, APO-Easy Genotyping Kit). The company provides biomarker services including proteomics (Olink, Quanterix platforms), genomics (NGS, Illumina NextSeq 500), and assay development. All products and services are supported by GMP-compliant facilities certified ISO 13485, ISO 17025, ISO 9001, and biobanking under NF S 96-900 standards.

Differentiator

Problem solved

Functional benefit

Brands

  • Firalis Molecular Precision: Subsidiary brand for large-scale protein identification and genomics services including Olink, Quanterix, and Next Generation Sequencing
  • Lodiag
  • FIMICS
  • NEUROLINCS
  • MEMORYLINC
  • BIOPRED

Products and services

  • FIMICS Long non-coding RNA (lncRNA) research-use-only panel quantifying 3,233 cardiac-enriched lncRNAs in peripheral blood samples for characterization of patients with diverse cardiac disorders and toxicities, leveraging NGS with ~55,000 capture probes.
  • MEMORYLINC Blood-based non-coding RNA RUO panel for early diagnosis of Alzheimer's disease and other neurodegenerative conditions.
  • NEUROLINCS Targeted sequencing RUO panel quantifying ~7,500 brain-enriched lncRNAs from blood samples for research on cognitive impairment, Alzheimer's, and neurodegenerative diseases.
  • BIOPRED mRNA targeted gene sequencing RUO panel quantifying over 2,100 mRNAs in whole blood (PAXgene RNA tubes) for inflammatory-autoimmune disorder research, using extraction-free HTG EdgeSeq chemistry with reproducibility mean R > 0.99.
  • ELISA Kits Colorimetric sandwich ELISA kits developed and validated by Firalis for quantitative biomarker measurement in blood-derived matrix samples.
  • EasyCOV COVID-19 Saliva Test CE-marked, non-invasive saliva-based IVD test using colorimetric detection for SARS-CoV-2, with HAS validation and reimbursement recommendation in France.
  • APO-Easy Genotyping Kit CE-IVDR certified qualitative IVD real-time PCR test for detection of APOE genotypes (rs429358 and rs7412) supporting Alzheimer's disease diagnostics and risk stratification.
  • Proteomics CRO Services (Olink / Quanterix Simoa) CRO biomarker services using Olink Explore, Target, and Flex Proximity Extension Assay platforms (92+ biomarkers per panel from <50 µl samples) plus Quanterix Simoa ultra-low protein quantification.
  • Genomics CRO Services (Illumina NextSeq 500 NGS) CRO genomics services delivering Illumina Propel-certified NextSeq 500 NGS including RNA-Seq, miRNA profiling, exome sequencing, methylation analysis, single-cell sequencing, spatial transcriptomics, and custom RT-qPCR.
  • Assay Development & Production Services CRO assay development, validation, and ISO 13485/ISO 17025-compliant production of biological materials and CE-marked IVD kits for pharma and diagnostic partners.
  • Clinical Samples / Biobank Services Clinical biological samples and biobanking services operated under NF S 96-900 certification, with Firalis' biobank moving toward registration as a BBMRI-ERIC node.
  • Recombinant Proteins / Calibrants Catalog of recombinant proteins and calibrants for research and diagnostic assay development.
  • Monoclonal Antibodies Catalog monoclonal antibodies for biomarker detection and diagnostic assay development.

Quantifiable outcome

  • 100+ clinical and pre-clinical biomarker research projects completed
  • +5 more outcomes

Companies that use Firalis

Customer profile

Named customers7 records

Segments3 records

Ideal customer profiles3 records

Firalis technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration7 records

AI capability8 records

Feature8 records

Firalis partnerships and signals

Strategic signal

Partnerships

23 partnerships are on record, tiered minor and core.

  • ONCOSCREEN Consortium (~40 partners)minorStrategic or Co-development Partner · 12 May 2025EU Horizon Europe project for colorectal cancer screening. €14 million project integrating AI, genomic biomarkers, and citizen feedback for early CRC detection.
  • VOLABIOS Consortium (18 partners)coreStrategic or Co-development Partner · 1 January 2025Horizon Europe project for schizophrenia diagnosis using multi-omics volatolomics biomarkers. Firalis leads VOC biomarker validation with genomics, proteomics, transcriptomics expertise.
  • Rostock Medicine UniversityminorStrategic or Co-development Partner · 24 June 2024CombiDiag doctoral network coordinator hosting summer school at Firalis for Alzheimer's biomarker research training.
  • ADAPT Centre at Trinity College DublincoreStrategic or Co-development Partner · 3 April 2023PARADISE project coordinator for personalized prediction tool for autoimmune disease recurrence. Project kick-off April 2023 for three-year duration.
  • Luxembourg Institute of Health (LIH)coreStrategic or Co-development Partner · 1 November 2020COVIRNA project coordinator for COVID-19 cardiovascular complications diagnostic test development. FIMICS panel based prognostic device development with 3.88 M€ EC funding.
  • OlinkcoreTechnology or Integration · 6 August 2020Olink certified service provider offering Proseek panels for COVID-19 research at exceptional prices. Each panel measures 92 biomarkers simultaneously.
  • SkillCellcoreStrategic or Co-development Partner · 18 June 2020EasyCOV saliva test production partnership for COVID-19 diagnostic. Firalis produces tests at industrial scale. HAS validated for use and reimbursement.
  • Sys2Diag/CNRScoreStrategic or Co-development Partner · 18 June 2020EasyCOV consortium partner for COVID-19 saliva test development with validation by French health authorities.
  • VOGOminorStrategic or Co-development Partner · 18 June 2020EasyCOV consortium partner providing technology startup expertise for COVID-19 diagnostic test development.
  • AstellasminorStrategic or Co-development Partner · 28 May 2019Japanese pharmaceutical company collaboration beginning for biomarker research services.
  • SanoficoreStrategic or Co-development Partner · 21 January 2019PACIFIC consortium partner (5-year project) for redefining heart failure with preserved ejection fraction (HFpEF). Sanofi leads consortium with Firalis providing biomarker expertise.
  • ServiercoreStrategic or Co-development Partner · 21 January 2019PACIFIC consortium partner contributing expertise in data management and biostatistics for heart failure research alongside Sanofi.
  • Assistance Publique - Hôpitaux de Paris (AP-HP)coreStrategic or Co-development Partner · 21 January 2019PACIFIC consortium coordinator for clinical study with five cardiology hospitals and clinical investigation centers recruiting patients.
  • InsermcoreStrategic or Co-development Partner · 21 January 2019PACIFIC consortium partner providing expertise in biomedical ultrasound and cardiovascular imaging analysis through research units.
  • BioserenityminorStrategic or Co-development Partner · 21 January 2019PACIFIC consortium partner developing connected textiles for remote patient monitoring in heart failure management.
  • CASISminorStrategic or Co-development Partner · 21 January 2019PACIFIC consortium partner developing AI image analysis software for cardiac imaging.
  • FealinxminorStrategic or Co-development Partner · 21 January 2019PACIFIC consortium partner developing AI algorithms for heart failure data analysis.
  • Celemics Inc.coreStrategic or Co-development Partner · 19 September 2018Co-development and commercialization agreement for FIMICS lncRNA panel using Celemics targeted enrichment technology for Next-Generation Sequencing. Joint product development.
  • HTG Molecular DiagnosticscoreTechnology or Integration · 23 May 2018Platform partner for Biopred panel development using HTG EdgeSeq system for extraction-free targeted mRNA profiling.
  • IlluminacoreTechnology or Integration · 20 May 2018Propel certified partner for NextSeq 500 sequencing platform ensuring high quality sequencing data and best practice compliance.
  • CHU de ToulousecoreStrategic or Co-development Partner · 17 June 2017HeartLinc project European clinical partner for AMI patient profiling (150 patients in France).
  • QuantaMatrixcoreStrategic or Co-development Partner · 24 March 2017Co-development and distribution agreement for IVD products in South Korea. Partner in HeartLinc project developing heart failure diagnostic test on Fi-MAP platform.
  • Seoul National University Hospital (SNUH)coreStrategic or Co-development Partner · 24 March 2017HeartLinc project partner for heart failure diagnostic test validation in Asian AMI patients (150 patients).

Scale indicators11 records

Recent moves7 records

Expansion highlights7 records

Firalis competitors and assessment

Company assessment

Broad incumbents

  • Qiagen: Qiagen is a global molecular sample-prep and diagnostic company offering companion diagnostics, IVD kits, and biomarker services. Broader portfolio but directly competes with Firalis on IVD assay development and pharmaceutical biomarker services for pharma partners.
  • Myriad Genetics: Myriad is an established molecular diagnostics company commercializing blood-based and tissue-based companion and IVD tests (e.g., myChoice HRD, Vectra). Firalis's IVD strategy for cardiovascular and neurodegenerative biomarkers follows a similar companion-diagnostic commercialization model at smaller scale.
  • Bio-Rad Laboratories: Bio-Rad provides life science research and clinical diagnostics products including ddPCR, digital ELISA, and biomarker kits. Overlaps with Firalis's ELISA kit offerings and proteomics CRO services for pharma and academic customers.

Direct peers

  • NanoString Technologies: NanoString offers spatial transcriptomics and targeted gene expression profiling (GeoMx, nCounter) serving the same pharma and translational research customer base as Firalis's genomics services, including direct overlap with Firalis's spatial transcriptomics service line.
  • Quanterix: Quanterix provides the Simoa ultra-sensitive protein detection platform used by Firalis as a certified service provider. Comparable biomarker detection technology for neurology and inflammation indications and overlapping pharma/biotech customer base in blood-based biomarker discovery.
  • Eurofins Genomics: Eurofins Genomics is a global genomic services and biomarker CRO offering NGS, qPCR, genotyping, and biomarker assay services to pharma and academic customers. Directly comparable to Firalis's genomics/transcriptomics CRO offering and competing for the same European pharma R&D budget.
  • HTG Molecular Diagnostics: HTG Molecular Diagnostics develops the EdgeSeq extraction-free targeted mRNA profiling platform that Firalis uses for the BIOPRED panel. Both serve pharma biomarker discovery with targeted RNA panels, making HTG a partner-and-competitor with direct product overlap in inflammatory-autoimmune profiling.

Emerging players

  • Biodesix: Biodesix is a blood-based diagnostics company developing proteomic and multi-omic tests for oncology and lung disease. Comparable as an emerging blood-based biomarker diagnostic company pursuing similar indications and reimbursement pathways as Firalis's MEMORYLINC and FIMICS.
  • QuantaMatrix: QuantaMatrix developed the Fi-MAP multiplexed gene-expression IVD platform used in the HeartLinc project with Firalis and Seoul National University Hospital. Overlapping focus on molecular diagnostics for infectious disease and cardiology with similar Asian market channel strategy.
  • Celemics: Celemics is a Seoul-based targeted NGS enrichment and sequencing company that co-developed the FIMICS panel with Firalis. Comparable as a smaller emerging player in the targeted sequencing/biomarker panel market and a partner-competitor for next-gen sequencing diagnostics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Firalis social profiles

Digital presence

Firalis compliance and trust

Trust signal

Compliance8 records

Firalis financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Firalis leadership team

Management profile

Number of profiles

Profiles4 records

Firalis subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Firalis funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Firalis M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Firalis

What does Firalis do?

Firalis provides biomarker discovery, development, and regulatory qualification services to pharmaceutical, biotech, and academic clients through its multi-omics CRO platform (proteomics, genomics, transcriptomics, assay development, biobanking). The company also manufactures and commercializes proprietary RUO and IVD biomarker kits — FIMICS (cardiac lncRNAs), BIOPRED (inflammatory mRNAs), NEUROLINCS and MEMORYLINC (neurodegenerative lncRNAs), ELISA kits, and IVD products such as EasyCOV (COVID-19 saliva test) and APO-Easy (Alzheimer's APOE genotyping). All production takes place in ISO 13485/ISO 17025/NF S 96-900 certified facilities in Huningue, France.

Is Firalis a public or private company?

Firalis is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Firalis founded?

Firalis was founded in 2008. It employs 11 to 50 people.

Where is Firalis based?

Firalis is headquartered in Huningue, France, in the Europe region.

How does Firalis make money?

Four revenue lines are on record. CRO Biomarker Services are the primary driver. The others are RUO and IVD Kit Sales, research Grants and CE-IVDR Certification Services.

Who are Firalis's main competitors?

Broad incumbents on record are Qiagen, Myriad Genetics and Bio-Rad Laboratories. Direct peers are NanoString Technologies, Quanterix, Eurofins Genomics and HTG Molecular Diagnostics. Emerging players are Biodesix, QuantaMatrix and Celemics.

Does Firalis have an API?

No public API is recorded for Firalis.

What industry is Firalis in?

Firalis's product category is Biomarker Diagnostics & Contract Research Services. Its primary akta.pro industry code is HLAAAMAJ, Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics), with a secondary code of HLAAAMAL, Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals